Profile Previews

Get a glimpse into our company and investor data—powered by the PitchBook Platform

Sandoz (Portfolio of 25 ANDAs)

M&A STATUS
Asset Purch. LATEST DEAL TYPE
1 FINANCING ROUNDS
Description

A portfolio of 25 U.S. FDA-approved abbreviated new drug applications. The portfolio includes ntecavir, an antiviral medication used in the treatment of hepatitis B viral infection (HBV).

Ownership Status
Acquired/Merged
Financing Status
Corporate Backed or Acquired
Primary Industry
Pharmaceuticals
Acquirer
CASI Pharmaceuticals
Primary Office
  • 100 College Road
  • West Princeton, NJ 08540
  • United States

Sandoz (Portfolio of 25 ANDAs) Valuation and Funding

Deal Type Date Amount Post-Val Valuation/
EBITDA
Debt Status

This information is reserved for PitchBook Platform users. To explore Sandoz (Portfolio of 25 ANDAs)‘s full profile, request access.

Request full access to PitchBook

Sandoz (Portfolio of 25 ANDAs) Former Investors

Investor Name Investor Type Holding Participating Rounds Investor Since Board Seat Contact Info

This information is reserved for PitchBook Platform users. To explore Sandoz (Portfolio of 25 ANDAs)‘s full profile, request access.

Request full access to PitchBook